Many anti-infectives inhibit the synthesis of bacterial proteins, but none selectively inhibits their degradation. Most anti-infectives kill replicating pathogens, but few preferentially kill pathogens that have been forced into a non-replicating state by conditions in the host. To explore these alternative approaches we sought selective inhibitors of the proteasome of Mycobacterium tuberculosis. Given that the proteasome structure is extensively conserved, it is not surprising that inhibitors of all chemical classes tested have blocked both eukaryotic and prokaryotic proteasomes, and no inhibitor has proved substantially more potent on proteasomes of pathogens than of their hosts. Here we show that certain oxathiazol-2-one compounds kill non-replicating M. tuberculosis and act as selective suicide-substrate inhibitors of the M. tuberculosis proteasome by cyclocarbonylating its active site threonine. Major conformational changes protect the inhibitor-enzyme intermediate from hydrolysis, allowing formation of an oxazolidin-2-one and preventing regeneration of active protease. Residues outside the active site whose hydrogen bonds stabilize the critical loop before and after it moves are extensively non-conserved. This may account for the ability of oxathiazol-2-one compounds to inhibit the mycobacterial proteasome potently and irreversibly while largely sparing the human homologue.
Proteasomes are structurally conserved from archaea to eukaryotes and are essential in eukaryotes 1 . The cytotoxicity of proteasome inhibitors has been exploited for cancer therapy 2 and suggested for the treatment of infections by eukaryotic pathogens, such as plasmodia and trypanosomes 3 . Unfortunately, the inherent toxicity of proteasome inhibitors is a drawback in the treatment of curable infections. Inhibitors that act with comparable potency on human proteasomes and proteasomes of infectious agents have not entered clinical practice as anti-infectives.
The only known bacterial pathogens with proteasomes are mycobacteria 4 . The tuberculosis pandemic has been declared a global health emergency as the growing resistance of M. tuberculosis to antibiotics 5 coincides with the spread of risk factors such as HIV/ AIDS and diabetes 6, 7 . Proteasomes degrade proteins that serve in signalling during adaptation, have become irreparably oxidized or are scavenged during starvation. The proteasome of M. tuberculosis is required for degradation of certain proteins 8, 9 , for it to survive nitroxidative stress in vitro 4 and for it to persist in mice 10 . The latter observation validates the M. tuberculosis proteasome as a drug target. However, all known proteasome inhibitors tested have inhibited mammalian proteasomes more potently than those of M. tuberculosis, including peptidyl epoxyketones, peptidyl aldehydes, c-lactam-blactones such as salinosporamide A (NPI0052) (ref. 11 and G. Lin et al., unpublished results) and the peptidyl boronate bortezomib (Velcade), which is in clinical use 2 . An effort to exploit the substrate preferences of the M. tuberculosis proteasome led to bortezomib analogues with varying amino acids at P1, the most selective of which inhibited the M. tuberculosis proteasome only eightfold more potently than a mammalian proteasome 12 .
Nonetheless, biochemical and structural differences between proteasomes from M. tuberculosis and mammals encouraged us to seek species-selective proteasome inhibitors. In eukaryotic proteasomes the seven types of b-subunit forming the two heteroheptameric inner rings of the core particle 13 include three proteases with distinct specificities for oligopeptides. The M. tuberculosis proteasome has one type of b-subunit 14, 15 , but it is active against diverse benzyloxycarbonylcapped tripeptides 14, 15 , perhaps because the side chains lining the active site of the M. tuberculosis proteasome have physicochemical properties that are a composite of those contributing to the three distinct active sites in eukaryotes 14, 15 . Until now, residues so distant from the active site as to have no role in binding of substrate were not considered germane to the species selectivity of inhibitors, including those listed above, that react with the catalytic hydroxyl of the aminoterminal threonine (Thr 1).
Mycobactericidal, non-cytotoxic proteasome inhibitors
We expressed M. tuberculosis proteasome from the genes encoding proteasome components A (for the a-chain) and B (for the b-chain) (PrcBA) with and without the N-terminal octapeptide deleted from the a-chains. The latter 'open-gate' mutant (M. tuberculosis 20SOG) is thought to mimic a physiological mechanism for gate opening and has a higher specific activity than the wild type without a change in substrate preference 12, 14, 15 . By following the hydrolysis of Suc-LLVY-7-amido-4methylcoumarin (AMC) by the M. tuberculosis 20SOG mutant, we screened 20,000 compounds (see Supplementary Information) and identified two inhibitors, 5-(5-methyl-2-(methylthio)thiophen-3-yl)-1,3,4-oxathiazol-2-one (GL5) and 5-(2-methyl-3-nitrothiophen-2yl)-1,3,4-oxathiazol-2-one (HT1171), as well as an inactive congener, 5-(5-methyl-2-(methylsulphonyl)thiophen-3-yl)-1,3,4-oxathiazol-2one (GL6) ( Fig. 1a ).
Like bortezomib, oxathiazol-2-one compounds were able to cross the cell wall of M. tuberculosis, insofar as GL5 and HT1171 inhibited proteasome activity on treatment of Mycobacterium bovis var. bacille Calmette-Guérin (BCG; Fig. 1b ). At 50 mM, GL5 and HT1171 inhibited ,90% of mycobacterial proteasome activity, whereas bortezomib (50 mM) inhibited 52%. Exposure of BCG to 25 mM GL5 for 4 h led to .80% reduction of proteasome activity ( Fig. 1c ), whereas as little as ,15 min exposure to GL5 at 50 mM was sufficient to reduce activity by ,50% (Fig. 1d ).
Moreover, GL5 killed BCG alone and in synergy with sub-bacteriostatic fluxes of nitric oxide arising from the decomposition of 2,2-(hydroxynitrosohydrazino)-bis-ethanamine (DETA-NO) (Supplementary Fig. 1 ). GL5 and HT1171 also dose-dependently killed 1.5-2.5 log 10 M. tuberculosis over 4 days in synergy with sufficient nitric oxide to induce a pathophysiologically relevant state of bacterial non-replication 16 (Fig. 1e ). Bortezomib was less mycobactericidal ( Fig. 1e ), and it was toxic to monkey epithelial cells ( Fig. 1f ) and human macrophages ( Supplementary Fig. 2 ). In contrast, GL5 and HT1171 showed no apparent toxicity to mammalian cells ( Fig. 1f and Supplementary Fig. 2 ) at concentrations up to 75 mM, 3,000-fold greater than those at which bortezomib killed the epithelial cells. The oxathiazol-2-one compounds exerted no antibacterial activity against Mycobacterium avium intracellulare, Staphylococcus aureus, Salmonella enterica var. Typhimurium or Pseudomonas aeruginosa (data not shown). Although some oxathiazol-2-one compounds were reported to react with thiols 17 , those studied here did not inhibit the thiol-dependent cathepsin B (data not shown). Moreover, 11 of 23 oxathiazol-2-one compounds tested were ,5% reactive with glutathione; the others reacted to a limited degree ( Supplementary Table  1 ). Thus, at a functional level, the oxathiazol-2-one compounds tested here seem to be relatively selective and nontoxic, although they may have additional targets.
Selective inhibition of mycobacterial proteasomes
The different impact of oxathiazol-2-one compounds on M. tuberculosis and mammalian cells prompted us to ask if these compounds differentially inhibit isolated mycobacterial and human proteasomes. In dialysis ( Fig. 2a ) and kinetic studies (Fig. 2b, c) , oxathiazol-2-one compounds inhibited M. tuberculosis proteasomes irreversibly ( Fig. 2a ), whereas inhibition of human proteasome b1, b2 and b5 sites was so minimal (Fig. 2b, c and Supplementary Table  1 ) as to preclude definition of a mode of inhibition. After establishing that oxathiazol-2-one compounds spontaneously hydrolyse in tissue culture medium to the corresponding amide with a half time (t 1/2 ) ranging from 7 to 180 min (Supplementary Table 2 ), we used partition ratios (the ratios of rate constants for catalysis and inactivation) to assess their relative potency 18 . By this measure, GL5 and HT1171 were .1,000-fold more effective against M. tuberculosis proteasomes than human proteasomes ( Fig. 2d and Supplementary Fig. 3a, b ). Inhibition was competitive with the substrate benzyloxycarbonyl-valylleucyl-arginyl-AMC (Z-VLR-AMC) ( Supplementary Fig. 3c, d) , indicating that the inhibitor binds at or near the active site, and was timedependent ( Supplementary Fig. 4 ). Potencies of all 21 oxathiazol-2-one compounds tested against wild-type M. tuberculosis proteasome correlated closely (r 2 5 0.82) with their potencies against the open-gate form ( Supplementary Fig. 5 ). Oxathiazol-2-one-treated M. tuberculosis proteasomes lost the ability to degrade not only oligopeptides, but also a protein substrate, b-casein ( Supplementary Fig. 6 ). In contrast, oxathiazol-2-one compounds were inactive or very weak inhibitors of trypsin (half-maximal inhibitory concentration (IC 50 ) . 50 mM), cathepsin B (IC 50 . 50 mM), matrix metalloproteinase-2 (IC 50 . and mycobacterial blaC-encoded b-lactamase, a serine proteaselike enzyme (IC 50 . 100 mM). Although GL5 reversibly inhibited a-chymotrypsin with K i 64 nM, antichymotryptic potency was minimal in 13 other oxathiazol-2-one compounds tested ( Supplementary Table  4 ). Supplementary Table 1 summarizes biochemical and mycobactericidal properties of 24 oxathiazol-2-one compounds, including 21 we synthesized as described in the Supplementary Information. Competitive, irreversible, mechanism-based inhibition indicated that the oxathiazol-2-one compounds inactivate the M. tuberculosis proteasome by covalent attack on the active site Thr 1. To test this, we trypsinized M. tuberculosis proteasomes that had been treated or not with HT1171. Results were identical for both wild-type and opengate forms. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) identified peptides representing 98% of the b-subunit. Only one peptide ion was unique to the M. tuberculosis proteasome b-subunit treated with HT1171 ( Fig. 3a ). Its mass was 26 Da higher than that of the N-terminal heptapeptide (TTIVALK) identified only in the untreated samples ( Fig. 3a and Supplementary Fig. 7a, b ), indicating the addition of a carbonyl at the expense of two hydrogen atoms ((1)R(2) in Fig. 3a ). MS/MS analysis of this modified peptide ( Supplementary Fig. 7a ) indicated that the modification was on one of the first two residues. To determine whether the N-terminal residue was modified, the tryptic peptides from untreated and treated M. tuberculosis proteasome b-subunits were subjected to reductive glutaraldehydation, which modifies amino groups of proteins and peptides 19 . Subjecting the trypsinized oligopeptides to reductive glutaraldehydation without prior exposure to oxathiazol-2-one increased the mass of the N-terminal heptapeptide by 136.13 Da, consistent with modification of two primary amines, those of Thr 1 and Lys 7 ( Fig. 3a , (1)R(3) and Supplementary Fig. 7c ). In contrast, applying the same procedure to proteasomes that had been pre-treated with HT1171 increased the mass of the same peptide by only 68.06 Da ( Fig. 3a, (2)R(4) and Supplementary Fig. 7d ), indicating that one primary amine was no longer available for reductive alkylation. MS/ MS analysis ( Supplementary Fig. 7d ) of this mono-alkylated peptide showed that only the lysine was modified, confirming that the N-terminal Thr was modified on HT1171 treatment. The mass spectrometric results were the same when HT1171 was replaced by GL5 or GL3 and when the proteasome was wild type or open-gate (not shown). These findings support the mechanism of inhibition shown in Fig. 3b : the attack of the oxathiazol-2-one by the OH of Thr 1 forms a carbonated or carbonothioated enzyme intermediate on Thr 1 that can either undergo hydrolysis to reactivate the enzyme, or donate a carbonyl to Thr 1 that links its a-amino and c-hydroxyl groups to form an oxazolidin-2-one, a chemically stable moiety 20 , consonant with the ability of oxathiazol-2-one compounds to cyclocarbonylate 1,2-aminoalcohols 21 .
Structural basis of species selectivity
To determine the basis for species selectivity, we solved four crystal structures: wild-type M. tuberculosis proteasome following exposure to GL1 at 2.4 Å resolution and to HT1171 at 2.5 Å resolution, and the open-gate variant (20SOG) alone at 2.5 Å resolution or following exposure to HT1171 at 2.9 Å resolution. N-terminal octapeptide deletion in the a-subunit of 20SOG did not alter the overall structure of the M. tuberculosis proteasome ( Supplementary Fig. 8a ). Furthermore, wild type and open-gate proteasomes underwent the same conformational changes (described later) on inhibitor treatment (Supplementary Fig. 8b ). The three structures ( Fig. 4, Supplementary Figs 8, 9 and Supplementary Table 5 ) each confirmed that oxathiazol-2-one compounds cyclocarbonylate Thr 1. Not only the oxazolidin-2-one ring, but also its protruding methyl group and carbonyl oxygen, were 
(3) (4) (1), HT1171-treated (2), treated with glutaraldehyde/Na(CN)BH 3 after trypsin digestion (3), or treated with glutaraldehyde/Na(CN)BH 3 after HT1171 treatment and trypsin digestion (4). All ions were confirmed by MS/MS analysis ( Supplementary Fig. 7a-d ).
Reaction equations illustrate proposed modification of active site Thr 1 by oxathiazol-2-one ((1)R(2)), and modification of primary amino groups at Thr 1 and Lys 7 with glutaraldehyde and Na(CN)BH 3 ( (1) resolved in the electron density (Fig. 4) . The oxazolidin-2-one ring is stabilized by a hydrogen-bond network involving Ala 180, Ser 141 and Asn 24 of the neighbouring b-subunit, and a water molecule in the substrate cavity ( Supplementary Fig. 9 ). Use of HT1171 and GL1 in the crystallographic studies and HT1171, GL5 and GL3 in the mass spectroscopic studies brought to four the number of oxathiazol-2-one compounds for which the same suicide-substrate inhibition mechanism was confirmed. Surprisingly, the substrate-binding pocket of the M. tuberculosis proteasome underwent a major conformational change on cyclocarbonylation of Thr 1 by HT1171 or GL1. Such a change is unprecedented among the dozens of crystal structures of proteasomes in complex with inhibitors 11 . An ,8u downward tilt of the H1 helix in the b-subunit moved the N-terminal end of H1 (Ala 49-Phe 55) downward by as much as 4.2 Å (Fig. 4b ). The H1 shift brought with it a 3-amino-acid stretch (Ala 46-Thr 48) of the S4 b-strand, converting this segment into a short loop (S4-H1). As a consequence, another short loop (Met 95-Gln 96-Gly 97) between H2 and S5 lost stabilizing contacts with the shifted components and became disordered, as illustrated by a black dashed curve in Fig. 4b . The S4-H1 loop region comprises the upper surface of the substrate-binding pocket 11, 14 . Its downward shift constricted the pocket to the point that it could not accommodate a peptide substrate, affording an additional mechanism of inhibition over and above incorporation of the active site hydroxyl into an oxazolidin-2-one.
In the native M. tuberculosis b-subunit, the three S4-H1 loop amino acids Ala 46, Gly 47 and Thr 48 are in b-strand configuration and form a b-sheet interaction with Leu 101, Ala 100 and Leu 99, respectively, in the S5 b-strand (Fig. 4c ). None of these residue pairs is conserved in the human proteasome b5 subunit and only one of them (Gly 47-Ala 96) in the human b1 and b2 subunits. One direct hydrogen bond and three pairs of water-mediated hydrogen bonds (Fig. 4d ). We speculate that the upper substrate-binding surfaces (S4-H1 loops) in the three catalytic b-subunits of the human proteasome might have difficulty breaking off from their corresponding b-sheet cores on initial modification of Thr 1 by oxathiazol-2-one compounds.
Thus, selectivity of oxathiazol-2-one compounds seems to be imparted in three ways: by the presence of a 1,2-aminoalcohol at the active site of the target, which, among enzymes, is likely to be limited to the N-terminal Thr hydrolase family; by the ability of the inhibitor to bind rapidly (before its spontaneous decay) and precisely adjacent to the 1,2-aminoalcohol; and by the degree to which the amino group of the 1,2-aminoalcohol has better access to the inhibitor's carbonyl (now attached to the alcohol) than water has. The protein landscape near the 1,2-aminoalcohol can thus determine species selectivity, both in how it binds the R group on the oxathiazol-2-one and in the conformations it adopts, that may either permit or limit access of water to the intermediate formed during reaction of the oxathiazol-2-one with the active site. Detailed understanding of the sequence of steps by which oxathiazol-2-one compounds cause a major conformational shift in the substrate-binding domain could guide the design of the next generation of inhibitors selective for the M. tuberculosis proteasome over the human proteasome.
Discussion
Non-replicating M. tuberculosis displays 'phenotypic tolerance', that is, relative resistance to conventional anti-infectives, imposing the need to treat tuberculosis longer than almost any other infectious disease. Prolonged treatment leads to interruption of therapy and emergence of hereditable drug resistance. Hence agents are needed that can kill M. tuberculosis when its replication is halted by conditions encountered in the host, such as those imposed by inducible nitric oxide synthase 22 . Oxathiazol-2-one compounds identified here phenocopy genetic deletion of the M. tuberculosis proteasome 10 by killing M. tuberculosis rendered non-replicative by exposure to sublethal nitric oxide. Along with thioxothiazolidines that inhibit the dihydrolipoamide acyltransferase of M. tuberculosis 16 , oxathiazol-2one compounds are only the second class of compounds, to our knowledge, that are selectively bactericidal for a non-replicating pathogen.
Certain oxathiazol-2-one compounds are selective in other ways as well. They inhibit the M. tuberculosis proteasome, but not the human proteasome N-terminal threonine b1, b2 or b5 proteases, cysteine proteases, serine proteases, or metalloproteases. They do not kill monkey epithelial cells, human macrophages or any bacteria we tested other than mycobacteria. The oxathiazol-2-one compounds react with proteasomes at their active site; however, residues distant from the active site, with which oxathiazol-2-one compounds do not interact, seem to impart species selectivity.
Inhibition of protein synthesis at the stages of transcription (for example, by rifamycins) or translation (for example, by aminoglycosides and capreomycin) are among the best validated antibiotic strategies 23 . It may prove synergistic to interfere at the same time with bacterial protein degradation. The ability of a brief exposure to oxathiazol-2-one compounds to inhibit M. tuberculosis proteasomes permanently is a potential advantage. M. tuberculosis may have difficulty replacing irreversibly inactivated proteasomes, not only when the protein synthesis of M. tuberculosis is markedly diminished in the non-replicative state 24 , but also when its protein synthesis is impaired by antibiotics.
Much of biology can be viewed as the interplay of two principles: conservation and diversity. The conservation of proteasomes across vast evolutionary distances is striking. The present work demonstrates that functionally exploitable diversity exists between the proteasomes of M. tuberculosis and its obligate human host.
METHODS SUMMARY
High-throughput screening was performed in 384-well plates with 33 mM test compounds. To test inhibition of proteasomes in intact mycobacteria, treated cells were centrifuged, washed twice and lysed mechanically, and aliquots (10 mg protein) of the supernatants assayed with Suc-LLVY-AMC (50 mM). Killing of DETANO-treated, non-replicating M. tuberculosis Erdman was tested in Sauton's medium, pH 7.4. After 4 days, samples were plated for enumeration of colony-forming units (c.f.u.) 3 weeks later. Monkey kidney cells were cultured in Dulbecco's Eagle's medium with 10% fetal bovine serum for cytotoxicity assessment after 48 h by tetrazolium reduction and microscopy. Recombinant M. tuberculosis proteasomes were purified as reported 15 . Human proteasomes were activated with PA28 (Boston Biochem). Kinetic studies were conducted in a Molecular Devices fluorescent plate reader with AMC-derivatized peptide substrates according to which proteasomal protease was being studied (M. tuberculosis or human b1, b2 or b5). Values of k obs were derived from the fit of data to equation (1) 
METHODS
High-throughput screen. Compounds from ChemDiv, ChemBridge, Spectrum, Prestwick Chemicals and Cerep were dissolved in DMSO and robotically dispensed to Falcon Microtest 384-well plates, with DMSO as vehicle control. After a 45-min preincubation with M. tuberculosis 20SOG (10 ml) at 37 uC, reaction buffer containing substrate (5 ml) was added. Final concentrations were as follows: test compounds, 33 mM; Suc-LLVY-AMC, 50 mM; M. tuberculosis 20SOG, 1 nM; HEPES, 20 mM; EDTA, 0.5 mM; pH 7.5. Plates were placed on an orbital shaker in a humidified incubator at 37 uC for 45 min. Fluorescence was recorded at excitation 360 nm, emission 460 nm. Z9 values were .0.5. We screened 20,400 compounds and picked 72 (0.35%) that gave inhibition $65%. Of these, inhibition was confirmed with 26 compounds; concentrationdependent activity was most potent for HT1171 and GL5. A search of the library with the core structure (1,3,4-oxathiazol-2-one) identified GL6. GL1 and GL3 were identified in commercial collections using SCIFINDER. GL1, GL3 and GL5 were purchased from TimTec and GL6 was purchased from ChemDiv. HT1171 was resynthesized and the other compounds listed in Supplementary Table 1 were synthesized at the Abby and Howard P. Milstein Chemistry Core Facility of Weill Cornell Medical College. Mycobactericidal activity. Initial experiments showed that GL5 killed M. bovis var. BCG in synergy with nitric oxide, which was provided from the decomposition of 2,2-(hydroxynitrosohydrazino)-bis-ethanamine (DETA-NO) at 50 mM ( Supplementary Fig. 1 ). In the experiment illustrated in Supplementary Fig. 1 , DETA-NO alone reduced but did not completely prevent replication of BCG, whereas in the experiments with M. tuberculosis illustrated in Fig. 1e , DETA-NO prevented replication without reducing viability as assessed by plating. M. tuberculosis Erdman was cultivated in Sauton's medium pH 7.4 with 0.4% L-asparagine, 0.2% glycerol and 0.02% Tween 80. Mid-log phase cultures (A 580 0.8-1.0) were diluted to A 580 0.05-0.1 and quantified by c.f.u. Mycobacteria were incubated with bortezomib, GL5 or HT1171 at indicated concentrations in the presence of DETA-NO (50 mM) in 96-well plates in 200 ml for 4 days, then serially diluted in PBS with 0.02% Tween 80, pH 7.2 and plated for c.f.u. determination on Middlebrook 7H11 agar plates with 10% Middlebrook OADC enrichment (Fig. 1e) . Impact of oxathiazol-2-one compounds on eukaryotic cells. Vero76 African green monkey kidney cells (ATCC CRL-1587) were cultured in DMEM containing 4.5 g l 21 glucose, 0.584 g l 21 L-glutamine, 1 mM pyruvate, 100 IU ml 21 penicillin, 100 mg ml 21 streptomycin and 10% fetal bovine serum. Fresh medium was supplied containing test compounds at 25 or 50 mM. At indicated intervals of 1-25 h, this medium was removed and fresh medium added without test compounds. After exposure (48 h) to GL5, HT1171 or bortezomib at indicated concentrations, viability was assessed by the CellTiter96 Aqueous Assay (Promega) for tetrazolium reduction according to the manufacturer's protocol. Human monocyte-derived macrophages were allowed to differentiate in vitro for 2 weeks. GL5 or bortezomib were added in DMSO at indicated concentrations (,1%). Photomicrographs were taken 1 week later. Titration of M. tuberculosis and human proteasome by GL5 or HT1171. GL5 or HT1171 at concentration 0.2-50 mM were incubated with 3 nM M. tuberculosis 20SOG or 0.5 nM Hu20S (from human red blood cells, purchased from Boston Biochem), 2 nM PA28 (eukaryotic proteasome activator, Boston Biochem) in assay buffer overnight (19 h) . The remaining activity of proteasomes was assayed with 50 mM Suc-LLVY-AMC at 37 uC. The plot of v i /v 0 versus I/E t was used to estimate the partition ratios 18 . Here v i is the velocity of enzymatic reaction in the presence of inhibitor, v 0 is the velocity of enzymatic reaction in the absence of inhibitor, E t is the total concentration of the active sites of the enzymes. In this experiment, E t of M. tuberculosis 20SOG is 42 nM counting the concentration of active sites (14 active sites for each M. tuberculosis proteasome core particle), and E t of Hu20S is 1 nM counting the concentration of active sites (two b5 active sites for each human proteasome core particle). Because GL5 did not completely inhibit the Hu20S activity in our experiment ( Supplementary  Fig. 3a, b ), its partition ratio as listed in Fig. 2b was significantly underestimated. Standard errors were less than 10%. Determination of mode of inhibition. Assays were conducted on a Spectra MAX Gemini plate-reader from Molecular Devices. Assay buffer containing 1 nM M. tuberculosis 20SOG was added to the GL5 (5 mM, final concentration) and Z-VLR-AMC (indicated concentrations ranging from 15 to 60 mM). The reaction progress was recorded by monitoring fluorescence at 460 nm (l ex 5 360 nm) for 60 min at 37 uC ( Supplementary Fig. 3c ). Values of k obs were derived from the fit of data to equation (1) (ref. 25) in Prism (GraphPad Software), and then were plotted against substrate concentration (Supplementary Fig. 3d ). The diminution in k obs with increasing concentration of substrate indicated that GL5 was a competitive inhibitor. The line was the fit of data to equation (2) (ref. 25) , where k inact is the maximal rate of enzyme inactivation, I is the concentration of inhibitor, K i is the dissociation constant for the inhibitor, S is the concentration of substrate and K m is the substrate concentration at which the reaction reaches half-maximal velocity.
Kinetics. Kinetic measurements were performed at 37 uC on a 96-well plate assay on a Spectra MAX Gemini plate-reader from Molecular Devices with 1.5 nM M. tuberculosis 20SOG, 5 nM M. tuberculosis 20SWT or 0.5 nM Hu20S plus 2 nM PA28 in 20 mM HEPES, 0.5 mM EDTA, pH 7.5, and 25 mM Suc-LLVY-AMC (for Hu20S b5 activity), 25 mM Z-LLE-AMC (for Hu20S b1 activity) or 25 mM Z-VLR-AMC (for h20S b2 activity). The release of AMC from substrate cleavage was monitored (l ex 5 360 nm, l em 5 460 nm) for 120 min. The k obs values were determined by fitting the raw data to equation (1) . The slopes of the plots of k obs versus I gave an apparent value of k obs /I, also referred to as k inact /K i for an irreversible inhibitor, which was then corrected by equation (3) to compensate for the effect of substrate competition, where app is the apparent value at different inhibitor concentrations ( Supplementary Figs 4, 5 and Supplementary  Table 1 ).
Inhibition of degradation of b-casein by M. tuberculosis 20SOG. M. tuberculosis 20SOG (final concentration 12 nM) was pre-incubated in the assay buffer with 10 mM GL5/GL6 at 37 uC for 1 h. b-Casein (Sigma) was added at a final concentration of 0.2 mg ml 21 . The mixtures were incubated at room temperature. Aliquots were withdrawn at 1, 2, 3 and 4 h, mixed with SDS-PAGE loading buffer and analysed by SDS-PAGE ( Supplementary Fig. 6 ).
Stability of oxathiazol-2-one compounds in RPMI medium. Oxathiazol-2-one compounds in DMSO (final concentration 75 mM) were added to RPMI medium, which mimics human extracellular fluid, using pyrazinamide (75 mM) as an internal control. The solutions were incubated at 37 uC and aliquots were withdrawn at designed time points for analysis by ultra performance liquid chromatography/MS (Waters). Normalized data were fitted to an exponential decay equation to yield the half time for each compound. LC-MS/MS analysis. M. tuberculosis 20SOG or M. tuberculosis 20SWT (415 mg ml 21 ; 8.2 mM active sites) in 20 mM HEPES, 0.5 mM EDTA, pH 7.5, was incubated with 500 mM HT1171, GL5 or GL3 at room temperature until the activity assay demonstrated that inactivation was complete. A control sample was incubated for the same time with an equivalent volume of DMSO. The samples were then run on a SDS-PAGE gel to separate aand b-subunits. The gel bands corresponding to untreated and inhibitor-treated PrcB were excised from the gel, reduced with 10 mM dithiothreitol, alkylated with 55 mM iodoacetamide and digested with sequencing grade modified trypsin (Promega) in ammonium bicarbonate buffer at 37 uC overnight. The digestion products were analysed by LC-MS/MS and LC-MS with Thermo LTQ Orbitrap and Applied Biosystems QSTAR mass spectrometers, respectively. One tenth of the digestion products for each sample was also analysed by MALDI-TOF with a PerSeptive MALDI-TOF DE-STR mass spectrometer. For LC-MS/MS analysis, each digestion product was separated by gradient elution with a Dionex capillary/nano-HPLC system that is directly interfaced with the mass spectrometer. MS/MS data were searched using the MASCOT search engine for identifying proteins and modifications ( Fig. 3a and Supplementary Fig. 7a-d) .
For in-gel modification of primary amine groups, gel slices of untreated and treated proteins were incubated with 500 mM sodium cyanoborohydride and 2.5% glutaraldehyde at 37 uC for 1 h. Reactions were stopped by addition of 1 M Tris-HCl. Note: sodium cyanoborohydride is toxic, glutaraldehyde is carcinogenic and mutagenic. All reactions were carried out in a fume hood. Protease selectivity of oxathiazol-2-one compounds. Although the oxathiazol-2-one GL5 displayed marked selectivity for the M. tuberculosis proteasome over the three human proteasome subunits, the question remained whether oxathiazol-2-one compounds might inhibit proteases of other classes, given that many heterocyclic compounds are irreversible protease inhibitors. Therefore, we tested oxathiazol-2-one compounds on bovine spleen cathepsin B, a cysteine protease, human matrix metalloproteinase 2 (gelatinase), a metalloprotease, and bovine a-chymotrypsin, a serine protease. Most oxathiazol-2-one compounds were not active or weak inhibitors of Cat B and MMP-2 with IC 50 values greater than 50 mM. Inhibition of a-chymotrypsin by GL5 and HT1171. GL6, which was inactive on the M. tuberculosis proteasome, inhibited a-chymotrypsin more potently than GL5, with IC 50 values of 0.1 and 0.4 mM, respectively. We further determined that inhibition of a-chymotrypsin by GL5 was not time-dependent (data not shown), indicating that it was reversible. Double-reciprocal analysis of inhibition at different concentrations of GL5 versus different concentrations of substrate demonstrated that GL5 was a competitive inhibitor of a-chymotrypsin, with K i 5 64 nM (not shown). However, other oxathiazol-2-one compounds showed only weak activity against bovine a-chymotrypsin (Supplementary Table 4 ). For example, the IC 50 for HT1171 was 18.9 mM. Glutathione reactivity of oxathiazol-2-one compounds. Oxathiazol-2-one compounds (10 mM) were spotted in a 96-well plate in triplicate. N-ethylmaleimide (NEM) (10 mM) and DMSO were used as positive and negative controls, respectively. An identical 96-well plate was prepared to serve as the blank. The working buffer (100 mM potassium phosphate, 2 mM EDTA, pH 7.0) with glutathione (25 mM) was added to each well on one plate and working buffer without glutathione was added to the blank plate. The plates were incubated for 30 min at room temperature, at which point 5,59-dithio-bis(2-nitrobenzoic acid) (DTNB; 100 mM) was added to each well. The plates were shaken and absorbance read at 405 nm. Percentage of reacted glutathione was calculated as % GSH reacted 5 (negative control 2 sample)/(negative control 2 positive control) 3 100. Purification and crystallization of the M. tuberculosis 20S proteasome. The wild-type M. tuberculosis proteasome was purified as described 14 . In our current work, we improved the sample preparation and crystallization conditions in order to obtain M. tuberculosis 20S proteasome crystals that diffracted to better than 3 Å resolution 14 . Briefly, the purified and concentrated M. tuberculosis proteasome was dialysed against 10 mM HEPES buffer at pH 7.5 for 12 h (with 0.2 M NaCl in the case of M. tuberculosis 20SOG). Then the sample was set up in crystallization plates with the sitting drop method at 4 uC. The crystallization droplet contained 3 ml of 20S proteasome at a concentration of 10 mg ml 21 , mixed with 3 ml of well solution containing 60 mM Na citrate (pH 5.8) and 13% PEG 6000 as the precipitant. The crystals with the approximate dimensions of 200 3 60 3 50 mm grew after 5-7 days. For cryo-crystallography, the crystal solution was replaced in several concentration steps with a cryo-protecting solution containing the original mother liquid and 35% dimethylformamide. For inhibitor soaking, the crystals were moved into the cryo-protecting solution containing 1 mM HT1171 or 1 mM GL1, and incubated at 4 uC for 10 to 14 h before the crystals were flash frozen.
Diffraction data collection and structure solution. X-ray diffraction data were collected at National Synchrotron Light Source in Brookhaven National Laboratory. The diffraction data were processed and scaled with the HKL2000 package 26 . The crystals of the M. tuberculosis 20S proteasome soaked with various inhibitors belonged to the same space group P21 (See Supplementary Table 5 for the statistics of the crystals). For crystals with unit cells different from our previously reported structure, molecular replacement was carried out using the program PHASER 27 with the published structure as search model (Protein Data Bank ID 2FGH) 14 and the top solution was subjected to rigid body refinement in CNS 28 . For crystals with the same unit cell parameters as our published structure, the native wild-type 20S structure was used directly to calculate the difference density maps. Structure refinement. The following is the refinement procedure for the structure of wild-type 20S soaked with HT1171; the structure of GL1 was refined in the same way. The two loop regions, Thr 48 to Val 53 and Gly 89 to Leu 101, were rebuilt according to the electron density in program Coot 29 . The refinement was carried out using CNS with simulated annealing protocol. Fourteen noncrystallographic symmetry (NCS) restraints were applied during the refinements. A composite omit map was calculated to verify the conformation of the S4-H1 loop region. Several rounds of manual rebuilding and refinement improved the R factor to a value of 24.2% for R work and 25.6% for R free . At this point, the oxazolidin-2-one structure covalently linked to Thr 1 was built into the model. The topology and parameter files were generated for oxazolidin-2one-modified Thr 1 with idealized geometry. The energy minimization and individual B-factor refinement were carried out with NCS restraints in CNS. Water molecules were then added. Certain residues had different conformations in different NCS-related subunits, and these side chains were fixed. The structure was further refined with relaxed NCS restraints. For the open-gated structures, further refinement of the model against the crystallographic data was achieved using the refinement program of PHENIX 30 , which included anisotropic scaling, bulk solvent correction, rigid body refinement, simulated annealing, NCS and TLS (Translation/Libration/Screw, determined by TLSMD server) refinement. In the final models, .99% of the residues are in the core and allowed regions of the Ramachandran plot. Refinement and model statistics for all structures are given in Supplementary Table 5 .
